GlassScriptPhysician profile
Gopal Rao
NPI 1447229885
$29,451.86
in general payments reported to CMS, 2019-2025
71 companies · $4,307 in 2025
The $4,307 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,541 · 2020: $3,755 · 2021: $6,459 · 2022: $4,559 · 2023: $3,518 · 2024: $3,313 · 2025: $4,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $83.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,054.33 |
| Education | $83.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,841.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,001.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,999.91 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Amgen INC. | $1,918.46 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $1,914.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,673.85 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $1,405.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $1,379.08 | 2021 | |
| Lilly USA, LLC | $1,264.25 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $935.47 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $852.77 | 2023-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $802.27 | 2019-2025 | |
| Esperion Therapeutics, INC. | $769.13 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $669.04 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $587.68 | 2021-2023 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopal Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.